Sensitivity of Various Indicators in a Mouse Sensitive Skin Model Treatment with 4-tert-Butylcyclohexanol and Pimecrolimus

TL;DR

This study tests how a mouse model of sensitive skin responds to two treatments, 4-TBLH and pimecrolimus, measuring various skin sensitivity indicators.

Contribution

The study introduces a detailed evaluation of a sensitive mouse skin model's responsiveness to different treatment timing and substances.

Findings

4-TBLH and pimecrolimus showed distinct effects on skin sensitivity indicators like TEWL, capillary dilation, and mast cell activity.

Prophylactic and therapeutic applications of both treatments revealed varied impacts on skin hydration, itching, and epidermal thickness.

The model demonstrated robust sensitivity to treatment factors, supporting its use for developing sensitive skin medications.

Abstract

The etiopathogenesis and treatment response of sensitive skin remain poorly understood. We used 4-tert-butylcyclohexanol (4-TBLH) and 1% pimecrolimus ointment to treat sensitive skin in mice models constructed using tape stripping, propylene glycol, and capsaicin. This study aimed to further investigate the sensitivity and responsiveness of this sensitive mouse skin model. Sensitivity and responsiveness were assessed by measuring transepidermal water loss (TEWL), skin hydration, skin flakes, vascular dilatation, itching, stinging, and histological changes, including mast cell, lymphocyte, and granulocyte infiltration, tumor necrosis factor-α (TNF-α) expression, and transient receptor potential vanilloid 1 receptor (TRPV1) expression. The application of 4-TBLH and pimecrolimus revealed distinct responses in skin sensitivity indicators, including TEWL, capillary dilation, and mass cell activity, depending on the treatment timing and substance used. The prophylactic and therapeutic applications of 4-TBLH revealed distinct responses in skin sensitivity indicators, including skin flakes, TEWL, itching, stinging, epidermal thickness, mast cell activity, TNF-α, and TRPV1 expression. The prophylactic and therapeutic applications of pimecrolimus ointment revealed distinct responses in skin sensitivity indicators, including skin flakes, skin water content, itching, epidermal thickness, mast cell activity, CD45, CD11b, TNF-α, and TRPV1 expression. The mouse sensitive skin model demonstrates robust sensitivity and responsiveness to different treatment factors, and the model can be applied to the development of prophylactic and therapeutic medications for sensitive skin.

Figures